Advertisements

Malex

Quick links to important sections

Malex

Advertisements

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Malex

What is Malex? Definition and Antimalarial Classification

Property Description
Active ingredients Pyrimethamine, Sulfadoxine
Form Oral tablet
Pharmacological class Antimalarial, Antiprotozoal
Common use Combating protozoal infections
Origin Synthetic drug

Malex is a synthetic, prescription-only medication classified as an Antimalarial and Antiprotozoal agent, provided for oral use in the form of a tablet. It is specifically designed as a Fixed-Dose Combination (FDC) product, containing the two distinct active pharmaceutical ingredients Pyrimethamine and Sulfadoxine. Pyrimethamine/Sulfadoxine combinations are recognized as essential for treating specific protozoal infections. This classification confirms the drug's role in public health measures against infectious diseases. The combination is clinically recognized for its efficacy in areas where drug resistance patterns necessitate this specific dual therapy, offering a well-established strategy for patient management.


Malex's Composition: A Dual-Action Antifolate

The core components of Malex are the two active ingredients, Pyrimethamine and Sulfadoxine, which are entirely synthetic compounds. Malex combines Pyrimethamine, a diaminopyrimidine, with Sulfadoxine, a member of the sulfonamide family. This composition creates a precise ratio that is essential for the product’s function, generating a powerful synergistic effect against the target organisms. The combination of these two agents is used to achieve a sequential blockade of the parasitic folate pathway. This synergy means the two ingredients work together to more efficiently suppress the infection, which has positioned this combination, also known by the brand name Fansidar, as a historically significant treatment option.


What is the General Therapeutic Purpose of this Combination?

The general purpose of Malex is to combat specific protozoal infections by disrupting the organisms' ability to produce essential compounds required for growth. This is achieved through a mechanism known as sequential blockade or dual antifolate action. The combined agents specifically interfere with the parasite’s internal processes to prevent the synthesis of folic acid, which the infectious entity needs to survive and multiply. A typical use scenario involves administering the medication to patients for the treatment of certain types of malaria infections, utilizing its ability to clear the parasitic load associated with the illness. The primary differentiation of this combination from newer antimalarials lies in its established, long-acting profile, although its use is often restricted to specific geographic areas based on resistance patterns.

Regulatory References

  1. U.S. National Library of Medicine notes that the combination of these two agents is used to achieve a sequential blockade of the parasitic folate pathway
Advertisements

What side effects are possible with Malex?

Possible Side Effects and Safety Information

The official safety profile for the Pyrimethamine/Sulfadoxine combination (Malex) classifies possible adverse reactions according to frequency and the body system affected, based on regulatory documentation.

Adverse effects listed in official labeling are commonly grouped into System-Organ Classes (SOCs), which include Blood and Lymphatic System Disorders, Skin and Subcutaneous Tissue Disorders, Gastrointestinal Disorders, Nervous System Disorders, and Hepato-biliary Disorders. Common and very common reactions frequently documented in the regulatory record include nausea, vomiting, diarrhea, headache, and anemia.

Serious Adverse Reactions

The regulatory record highlights the potential for rare but severe adverse reactions, which can include life-threatening conditions such as Severe Cutaneous Reactions (including Stevens-Johnson syndrome and Toxic Epidermal Necrolysis), Severe Hematological Disorders (such as agranulocytosis and aplastic anemia), and Fulminant Hepatic Necrosis. These serious events have been reported with sometimes fatal outcomes in the regulatory documentation.

Population-Specific Safety Considerations

Safety constraints are explicitly documented for certain populations. The medicine is contraindicated in patients with known hypersensitivity to the active ingredients or to sulfonamide drugs, as well as in those with megaloblastic anemia due to folate deficiency. Caution is advised for individuals with G6PD deficiency, due to the risk of hemolytic anemia, and for patients with existing severe renal or hepatic impairment. Official guidance generally advises against use during the first trimester of pregnancy.

Time-Related Patterns and Limitations

The label notes that certain mild, transient side effects may be more pronounced following the first dose of the medicine. Regulatory safety documentation specifies that treatment must be discontinued upon the first appearance of a skin rash or if evidence of severe blood dyscrasias is noted.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

Suspected overdose involving Malex requires immediate medical attention and contact with emergency medical services, as described in regulatory prescribing information. Overdose with this fixed-dose combination may present with acute signs of toxicity affecting the central nervous system (CNS) and the hematopoietic system. Documented clinical manifestations can include CNS excitement and severe episodes of convulsions, along with gastrointestinal effects such as anorexia and vomiting. Acute or chronic toxicity may lead to delayed, life-threatening complications, including severe hematological toxicity such as megaloblastic anemia, leukopenia, and thrombocytopenia.

In cases of acute ingestion, management procedures specified in official labels include symptomatic and supportive treatment, along with consideration for gastric lavage and administration of activated charcoal. No specific antidote is known for the drug itself; however, regulatory sources mandate the administration of Folinic Acid (Leucovorin) to counteract the hematologic toxic effects resulting from the drug's antifolate activity. Hospital monitoring is required, specifically including frequent monitoring of blood counts and renal function, as the risk of severe toxicity is known to be increased in patients with pre-existing hepatic or renal impairment.

Advertisements

Therapeutic Uses of Malex

What Malex Treats: Main Uses and Benefits

Malex is commonly used in conditions presenting with systemic discomfort and acute, disruptive episodes of uncomplicated Plasmodium falciparum malaria. It is applied across domains where additional symptomatic support is needed to address the sudden appearance of high fevers, chills, and malaise. This is generally used in situations where symptomatic discomfort is associated with acute or disruptive episodes. This use provides support that helps ease the overall symptom burden of the active infection and may assist with maintaining functional stability.

The primary therapeutic applications include the curative treatment of P. falciparum malaria, Intermittent Preventive Treatment (IPT) in high-risk groups, and prophylaxis for opportunistic infections like Pneumocystis jiroveci pneumonia (PJP). This scheduled use is considered relevant for easing the infectious burden in endemic areas. A primary therapeutic benefit is its use in preventive strategies for vulnerable populations. This strategy supports general well-being during symptomatic phases and may be relevant in contexts where additional management of discomfort is required.

Quick Fact: Relief for Acute Febrile Symptoms

Regulatory References

  1. World Health Organization (WHO) Prequalification Program
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Malex?

The population eligibility for Malex (Pyrimethamine/Sulfadoxine) is defined by strict regulatory guidelines, establishing absolute contraindications and conditions that require restricted use.


Absolute Contraindications

Malex is contraindicated and must not be used in the following groups:

  • Patients with documented megaloblastic anemia due to folate deficiency.
  • Patients with known hypersensitivity to pyrimethamine or sulfonamide drugs.
  • Infants less than 2 months of age.
  • Pregnant women in the first trimester and at term (near delivery).
  • Patients with severe renal failure, hepatic failure, or blood dyscrasias if repeated prophylactic use is intended.

Age and Physiological Restrictions

Population Group Eligibility Status
Infants/Children Contraindicated under 2 months of age; Approved for children 2 months.
Adults Approved for treatment and prophylaxis of malaria.
Pregnancy Contraindicated in 1st trimester/at term; Permitted for IPTp in 2nd/3rd trimesters.

Use with Caution

Caution is advised for use in patients with impaired renal or hepatic function when used for treatment, as well as individuals with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency. Furthermore, the medicine is not recommended for HIV-positive patients already receiving co-trimoxazole prophylaxis.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Malex (Pyrimethamine/Sulfadoxine) is defined by officially documented restrictions based on additive toxicity and pharmacodynamic effects, as specified in government regulatory labeling.

Contraindicated and Restricted Combinations

Interacting Substance Regulatory Constraint Rationale
Antifolic Drugs (e.g., Trimethoprim/Sulfamethoxazole) Co-administration is restricted. Increased risk of hematological side effects.
Myelosuppressive Agents (e.g., Methotrexate, Zidovudine, Proguanil) Co-administration is restricted. Potential for additive bone marrow suppression.

Pharmacodynamic and Toxicity Notes

The risk of hepatic and hematological adverse effects may increase if Malex is given with other drugs with known hepatic or hematological toxicity. Furthermore, Folic Acid at a daily dose equal to or above 5 mg is restricted because it formally counteracts the efficacy of the antimalarial component. Co-administration with Chloroquine has also been associated with an increase in the severity of adverse reactions.

Administration and Population Constraints

A mandatory timing rule requires that the product should not be given if the patient has received Pyrimethamine/Sulfadoxine in the past 30 days. Additionally, repeated prophylactic use is contraindicated in patients with renal failure or hepatic failure, and in those with documented folate deficiency.

Advertisements

Mechanism of Action

Targeting the Parasite's Folate Synthesis Pathway

The mechanism of Malex is a precise, dual-action approach known as sequential blockade that disrupts the organism's ability to synthesize tetrahydrofolic acid (THF), a vital molecule. The two active ingredients target distinct, successive steps in the protozoal organism's folate pathway: Sulfadoxine inhibits the enzyme dihydropteroate synthase (DHPS), while Pyrimethamine inhibits dihydrofolate reductase (DHFR).


Synergy and Arrest of Replication

This simultaneous inhibition creates synergy, ensuring a near-complete shutdown of the pathway greater than the effect of either component alone. THF is essential for the organism to produce purine and pyrimidine bases, which are the building blocks of DNA and RNA. The resulting deprivation of nucleic acid synthesis halts the organism's ability to divide and multiply, leading to a parasitostatic effect and the suppression of organism proliferation.


Mechanism Limitations and Enzyme Resistance

The activity of this sequential blockade is constrained by the organism's ability to genetically modify its target enzymes. Point mutations in the DHPS or DHFR binding sites can reduce the affinity of Sulfadoxine or Pyrimethamine, functionally bypassing the molecular block. When this happens, the organism can partially restore its folate synthesis and, consequently, its ability to undergo cell division, which reduces the magnitude of the replication blockade.

Advertisements

Dosage and Administration Information

How Malex is Used: Official Administration and Dosing Principles

Malex (sulfadoxine and pyrimethamine), an Antimalarial and Antiprotozoal agent, is approved for oral administration as a tablet containing 500 mg of sulfadoxine and 25 mg of pyrimethamine. The administration instructions define its use, requiring the tablets to be swallowed whole and taken after a meal or with food, alongside a substantial intake of fluids. This practice is specified to support proper administration and is part of the official procedural guidance.


Official Dosing Regimens and Frequency

Distinct dosing patterns are established based on the intended use, which determine the amount and frequency of administration:

  • Acute Treatment: For managing certain uncomplicated infections, the standard adult regimen is a single, one-time dose of 2 to 3 tablets (delivering 50/1000 mg to 75/1500 mg of the combination).
  • Prophylaxis: When used to prevent infection, the medication is administered on an intermittent schedule, such as 1 tablet once weekly or 2 tablets every two weeks. Prophylaxis must begin 1 to 2 days before entering the endemic area and must continue for 4 to 6 weeks after departing.

Use in Specific Populations

Guidelines are established for specific patient groups. For children over 2 months of age, the appropriate dose for both treatment and prevention is calculated based on body weight in kilograms. Additionally, caution is advised for patients with existing hepatic or renal impairment, and the repeated prophylactic use of Malex is generally contraindicated in cases of established renal or hepatic failure.

These official instructions define the standardized, procedural structure for the drug's administration across different use contexts.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of Studies for Malex


Evidence for Intermittent Preventive Treatment in Pregnancy (IPTp)

The use of the Malex combination (Pyrimethamine/Sulfadoxine) has been evaluated in numerous Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews to explore the scheduled use in pregnancy. This research focused on pregnant women residing in areas where the disease is widespread. Studies monitored several critical outcomes related to maternal and infant health, including measurements of Severe Maternal Anemia, Low Birth Weight (LBW) in newborns, and the presence of Placental Malaria Infection.

Studies reported measurements of placental parasite load and maternal anemia status across the course of the research. What remains uncertain is the full impact of increasing parasite drug resistance across various global regions, which is acknowledged in research as a factor affecting consistency.


Evidence for Uncomplicated P. falciparum Malaria Treatment

Research exploring Malex for use during acute P. falciparum malaria episodes primarily relies on short-term Clinical Trials and ongoing Observational Efficacy Surveillance Studies. These studies research examined the time required for parasite clearance and the proportion of patients who experienced clinical failure (or recurrence) over observation periods typically lasting 28 to 42 days.

Research describes patterns related to the drug's application being heavily influenced by the local drug resistance profile of the parasite. While historical trials describe its past role, contemporary research indicates its application is now concentrated on specific contexts because of evolving resistance. Evidence is limited for the combination’s use in regions with high levels of resistance, and the results apply only to the populations studied during the trial periods.


Evidence for Prophylaxis of Opportunistic Infections (PJP)

The combination was studied for use in prophylactic strategies against opportunistic infections, such as Pneumocystis jiroveci Pneumonia (PJP), in immunosuppressed patients. Research has explored this through Prospective and Retrospective Cohort Studies that monitored the occurrence of new or recurring cases of pneumonia. Much of this foundational evidence is older, reflecting treatment protocols established before modern, highly effective treatments became standard.

Key Studies & References Pyrimethamine/Sulfadoxine (Fansidar) DailyMed/NIH: Dosage Forms, Classification, Mechanism

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Malex (FAQ)

Q: Does Malex interact with alcohol?

A: Official patient guidance for this medicine advises against consuming alcohol while taking the drug. The official product information describes this as a precaution.

Q: How long after stopping Malex does the drug stay in my system?

A: The medicine is a combination of two ingredients that have different elimination times. According to official pharmacokinetic data, the half-life of one component is typically 4 to 5 days, while the other component has a longer half-life, reported to be around 7 to 10 days. Due to this longer half-life, traces of the drug can be detectable for several weeks.

Q: Why do official documents use complex language to describe Malex's purpose?

A: Official documents must use precise, technical language to describe the drug's mechanism of action. This description details how Malex works by using a specific dual-action process, called sequential blockade, that prevents the target organism from producing essential compounds needed for its growth and multiplication.

Q: Can Malex be used long-term?

A: Regulatory documentation specifies the administration of this medicine for either a single, one-time dose in acute treatment, or for an intermittent prophylactic schedule lasting typically 4 to 6 weeks. Furthermore, repeated prophylactic use of the medicine is restricted in patients with severe renal or hepatic failure.

Q: How long does it typically take for Malex to start working?

A: According to pharmacokinetic data, the maximum concentration of the drug in the blood plasma is typically reached approximately 2 to 8 hours after taking the oral dose. This indicates when the concentrations of the drug in the bloodstream are measured at their peak.

Q: Is it normal to feel tired after starting Malex?

A: Fatigue and unusual tiredness are documented within the official safety profile as possible side effects reported with this medicine.

Q: Are there any specific foods or drinks to avoid when taking Malex?

A: Official patient information advises against consuming alcohol. Additionally, co-administration with certain products, such as antacids, is noted in regulatory information as potentially affecting the drug's absorption.

Q: Does taking Malex affect my ability to drive?

A: Regulatory information notes that because the medicine may cause side effects like dizziness, patient guidance includes a caution regarding driving or operating machinery.

Q: Can someone with diabetes use Malex?

A: Official guidance contains a specific caution regarding the use of this medicine in patients who have diabetes. This caution notes the potential for the medicine to be associated with low blood sugar, which is known as hypoglycemia.

Q: Will Malex make me feel 'high' or different?

A: Regulatory safety information lists nervous system and psychiatric adverse reactions, including feelings such as mental depression, nervousness, confusion, and hallucinations. These are documented possibilities noted in the safety information.

Q: Is Malex associated with any mood changes?

A: The official safety profile includes psychiatric adverse reactions such as depression and nervousness. These are documented possibilities noted in the safety information.

Q: Does Malex affect sleep?

A: Sleep problems, including insomnia, are listed in the official safety profile as a possible adverse reaction associated with the medicine.

Q: Is there a generic version of Malex available?

A: The medication is a combination of two generic active ingredients: pyrimethamine and sulfadoxine. The combination has been historically known by the brand name Fansidar.

Q: Does Malex affect blood pressure?

A: Regulatory safety information reports rare occurrences of cardiovascular effects, including circulatory collapse and disorders of cardiac rhythm. These effects relate to the circulatory system.

Q: Is there a chance Malex will stop working over time?

A: The drug's mechanism section and research summaries note that the parasite can develop resistance through genetic changes (point mutations) in its enzymes, which can reduce the drug's effectiveness against the organism's ability to divide.

Q: Can Malex interfere with lab test results?

A: Official guidance advises that laboratory tests, including complete blood cell counts and liver and kidney function tests, may be performed while using this medicine to monitor for potential side effects.

Q: Is there a maximum time someone can be on Malex?

A: The maximum duration of use is defined by the official dosing regimens. This is defined as a single, one-time dose for acute treatment, or an intermittent schedule for prophylaxis lasting typically 4 to 6 weeks.

Q: Why is Malex sometimes prescribed over other available options?

A: The combination is described as being used in specific contexts, particularly in areas where the local drug resistance profile of the parasite makes this dual-therapy approach a documented strategy.

Q: Are the initial side effects of Malex temporary?

A: Regulatory safety documentation notes that certain mild, transient side effects may be more pronounced following the first dose of the medicine.

Q: Can Malex worsen existing mental health conditions?

A: Official guidance notes that this medicine has been associated with psychiatric adverse reactions such as mental depression and nervousness.

Q: Is Malex approved by the FDA?

A: The pyrimethamine/sulfadoxine combination is a long-established medication. FDA labeling for the component pyrimethamine indicates its use for the treatment of toxoplasmosis when used with a sulfonamide, while its use for malaria prophylaxis has been restricted due to resistance.

Q: Are there different forms (tablet, capsule, liquid) of Malex available?

A: The official product information specifies the drug is an oral tablet for administration.

Advertisements

How should Malex be stored and disposed of?

The storage and disposal of Malex (Pyrimethamine/Sulfadoxine) must strictly follow the official conditions documented in the medicine's regulatory labeling.

Storage Conditions

Requirement Constraint
Temperature Store at room temperature, typically below 30°C. Do not freeze.
Protection Keep the tablets protected from light and moisture to maintain product stability.
Packaging Store in the original package or container.
Child Safety Must be stored out of the reach and sight of children.

Disposal

Unused or expired Malex must not be kept. Disposal must be managed in accordance with local requirements for unused medicinal products. Regulatory documents often state no special hazardous handling requirements for this product. If discarding in household trash, scratch out all identifying information on the original label.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Malex found in:

A-Z Index: